Germany
· Delayed Price · Currency is EUR | Market Cap | 1.31B |
| Revenue (ttm) | 788.22M |
| Net Income (ttm) | -206.98M |
| Shares Out | 177.60M |
| EPS (ttm) | -1.17 |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 614,040 |
| Average Volume | 1,400,662 |
| Open | 7.32 |
| Previous Close | 7.35 |
| Day's Range | 7.22 - 7.58 |
| 52-Week Range | 5.06 - 10.66 |
| Beta | 1.11 |
| RSI | 56.83 |
| Earnings Date | Apr 17, 2025 |
About Evotec SE
Evotec SE operates as drug discovery and development partner for the pharmaceutical and biotechnology industry worldwide. It operates in two segments, Shared R&D and Just Evotec Biologics. The company is developing pharmaceutical products in various therapeutic areas, such as oncology, autoimmune, cancer, diabetes, heart failure, fibrosis, immunology, pain and inflammation, infectious, kidney, liver, rare, respiratory, fibrotic and metabolic disease; central nervous system (CNS) and cardio metabolic disorders; and animal and women health. The c... [Read more]
Financial Performance
In 2024, Evotec SE's revenue was 796.97 million, an increase of 1.99% compared to the previous year's 781.43 million. Losses were -196.08 million, 133.7% more than in 2023.
Financial StatementsNews
Evotec Receives $ 2.5 m Grant to Generate Next Generation Tuberculosis Treatments
Gates Foundation supports Evotec with a $ 2.5 M grant to generate critical data supporting development of next generation tuberculosis drug combinations.The collaboration continues a successful partne...
Evotec Receives $ 2.5 m Grant to Generate Next Generation Tuberculosis Treatments
Gates Foundation supports Evotec with a $ 2.5 M grant to generate critical data supporting development of next generation tuberculosis drug combinations. The collaboration continues a successful partn...
Evotec Secures $2.5M to Innovate TB Treatments!
Evotec SE's $2.5 million grant from the Gates Foundation marks a significant leap in the fight against tuberculosis, aiming to shorten treatments and combat drug resistance globally. Jetzt den vollstä...
EQS-News: Evotec receives $ 2.5 m grant to generate next generation tuberculosis treatments
EQS-News: Evotec SE / Key word(s): Miscellaneous Evotec receives $ 2.5 m grant to generate next generation tuberculosis treatments 07.05.2025 / 07:30 CET/CEST The issuer is solely responsible for the ...
Evotec SE 2025 Q1 - Results - Earnings Call Presentation
Evotec SE (EVO) Q1 2025 Earnings Call Transcript
Evotec SE Reports Q1 2025 results: Paving the Way for 2025 Growth in Soft Market Environment
Group revenues of € 200 m, on track towards guidance; Shared R&D with similar trend as 2024; Just - Evotec Biologics with continuing growth momentumStrong progress in strategic protein degradation par...
Evotec SE Reports Q1 2025 results: Paving the Way for 2025 Growth in Soft Market Environment
Group revenues of € 200 m, on track towards guidance; Shared R&D with similar trend as 2024; Just - Evotec Biologics with continuing growth momentum Strong progress in strategic protein degradation pa...
Evotec SE Drives Growth with Strong Q1 2025 Results in Soft Market
Evotec SE's Q1 2025 results highlight strategic growth and innovation, with revenues surpassing expectations and promising future projections. Jetzt den vollständigen Artikel lesen
Earnings Preview: Evotec
Evotec (NASDAQ: EVO) is preparing to release its quarterly earnings on Tuesday, 2025-05-06. Here's a brief overview of what investors should keep in mind before the announcement. Analysts expect Evot...
Evotec SE to Announce Results for the First Quarter 2025 on 6 May 2025
HAMBURG, DE / ACCESS Newswire / April 29, 2025 / Evotec SE (Frankfurt Stock Exchange: EVT, MDAX/TecDAX, ISIN: DE0005664809; NASDAQ: EVO) will announce its interim statement for the first quarter of 20...
Evotec SE to Announce Results for the First Quarter 2025 on 6 May 2025
HAMBURG, DE / ACCESS Newswire / April 29, 2025 / Evotec SE (Frankfurt Stock Exchange: EVT, MDAX/TecDAX, ISIN: DE0005664809; NASDAQ: EVO) will announce its interim statement for the first quarter of 20...
EQS-News: Evotec SE to announce results for the first quarter 2025 on 6 May 2025
EQS-News: Evotec SE / Key word(s): Quarter Results Evotec SE to announce results for the first quarter 2025 on 6 May 2025 29.04.2025 / 10:02 CET/CEST The issuer is solely responsible for the content o...
Evotec Announces Significant Progress in Strategic Protein Degradation Collaboration with Bristol Myers Squibb
Key scientific achievements expand the pipeline of high value molecular glue degraders for unmet medical needsPerformance-based and program-based payments of in total US$ 75 m to Evotec HAMBURG, DE / ...
Evotec Announces Significant Progress in Strategic Protein Degradation Collaboration with Bristol Myers Squibb
Key scientific achievements expand the pipeline of high value molecular glue degraders for unmet medical needs Performance-based and program-based payments of in total US$ 75 m to Evotec HAMBURG, DE /...
Evotec & Bristol Myers Squibb: Breakthrough in Protein Degradation
Evotec SE and Bristol Myers Squibb are pioneering the future of medicine with their groundbreaking collaboration on molecular glue degraders, aiming to transform therapeutic landscapes and address unm...
EQS-News: Evotec announces significant progress in strategic protein degradation collaboration with Bristol Myers Squibb
EQS-News: Evotec SE / Key word(s): Miscellaneous Evotec announces significant progress in strategic protein degradation collaboration with Bristol Myers Squibb 24.04.2025 / 07:30 CET/CEST The issuer i...
Evotec SE (EVO) Q4 2024 Earnings Call Transcript
Evotec SE (NASDAQ:EVO) Q4 2024 Earnings Conference Call April 17, 2025 8:00 AM ETCompany ParticipantsVolker Braun - Head of Investor RelationsChristian...
Evotec SE 2024 Q4 - Results - Earnings Call Presentation
The following slide deck was published by Evotec SE in conjunction with their 2024 Q4 earnings call.
Evotec SE (EVO) Reports Q4 Revenue Boost, Forecasts Strong Future Growth
Evotec SE (EVO) Reports Q4 Revenue Boost, Forecasts Strong Future Growth
Earnings Scheduled For April 17, 2025
Companies Reporting Before The Bell • Evotec (NASDAQ: EVO) is estimated to report quarterly loss at $0.01 per share on revenue of $250.69 million. • Taiwan Semiconductor (NYSE: TSM) is expected to r...
Evotec SE reports Q4 results; initiates outlook for FY25 and FY28
Evotec SE Unveils New Strategy and Provides 2025 Guidance Bolstered by Strong Q4 2024 Results
Evotec sharpens focus on pioneering drug discovery and charts clear path toward sustainable profitable growthStrategy builds on technology and science leadership, focusing on high-growth, high-value s...
Evotec SE Unveils New Strategy and Provides 2025 Guidance Bolstered by Strong Q4 2024 Results
Evotec sharpens focus on pioneering drug discovery and charts clear path toward sustainable profitable growth Strategy builds on technology and science leadership, focusing on high-growth, high-value ...
Evotec's Bold 2025 Strategy Boosted by Stellar Q4 2024 Results
Evotec SE is setting the stage for a transformative journey in drug discovery, blending innovation with strategic growth to navigate and thrive in a competitive market. Jetzt den vollständigen Artikel...